Molecular Genetics Laboratory of Female Reproductive Cancer

homepage photo

The long-term objectives of our research team are to:

  • understand the molecular etiology of female reproductive cancers
  • elucidate the mechanics of chemoresistance in ovarian cancer
  • translate basic research into potential clinical promise

We use ovarian carcinoma as a primary disease model because it is one of the most aggressive neoplastic diseases for women. Our research team aims to understand the molecular basis behind how normal cells are transformed, selected, and evolve to become invasive carcinoma. Genome-wide analyses at Hopkins have identified molecular genetic alterations in different types of ovarian cancers including NOTCH3, ARID1A, PIK3CA, PPP2R1A, among several others. We are currently focusing on revealing the tumor-promoting functions of NOTCH3 signaling and tumor-suppressor functions of the ARID1A pathway. In addition, we are characterizing metabolic reprograming during the development of platinum drug resistance. The ultimate goal is to translate our research findings into new preventive and therapeutic strategies. We are in collaboration with a team of dedicated clinicians and scientists across multiple disciplines to achieve this goal.

» Click here for the Ovarian Cancer Prevention Website

» Click here for the Ovarian Cancer Research Program

"What we observe is not nature itself, but nature exposed to our method of questioning."
-- Werner Heisenberg, Physics and Philosophy, 1958

Tian-Li Wang, PhD

Tian-Li Wang, PhD

Professor; Director of the Molecular Genetics Laboratory of Female Reproductive Cancer
Departments of Pathology, Oncology, and Gynecology & Obstetrics
Faculty in Pathobiology Graduate Program
Johns Hopkins Medical Institutions

National Taiwan University, BS
Johns Hopkins University School of Medicine, PhD
University of Pennsylvania, School of Medicine, Post-doc fellow (Neuroscience)
Howard Hughes Medical Institutions, Associate (Cancer Genetics)